Nuvation Bio Inc (NUVB) Q4 2025 Earnings Call Highlights: Strong Market Acceptance of Erozi ... [Yahoo! Finance]
Nuvation Bio Inc. Class A (NUVB)
Company Research
Source: Yahoo! Finance
This article first appeared on GuruFocus Total Revenue (Q4 2025): $41.9 million, including milestone payments. Total Revenue (Full Year 2025): $62.9 million. Net US Product Revenue for Ebrosi (Q4 2025): $15.7 million. Net US Product Revenue for Ebrosi (Full Year 2025): $24.7 million. R&D Expenses (Q4 2025): $34.3 million. R&D Expenses (Full Year 2025): $115.1 million. G&A Expenses (Q4 2025): $40.3 million. G&A Expenses (Full Year 2025): $151.6 million. Cash, Equivalents, and Marketable Securities (End of 2025): $529.2 million. New Patients Started on Ebrosi (Full Year 2025): 432 patients. New Patients Started on Ebrosi (Q4 2025): 216 patients. Warning! GuruFocus has detected 5 Warning Signs with NUVB. Is NUVB fairly valued? Test your thesis with our free DCF calculator. Release Date: March 02, 2026 For the complete transcript of the earnings call, please refer to the full earnings call transcript Positive Points Nuvation Bio Inc ( NYSE:NUVB ) receive
Show less
Read more
Impact Snapshot
Event Time:
NUVB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NUVB alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NUVB alerts
High impacting Nuvation Bio Inc. Class A news events
Weekly update
A roundup of the hottest topics
NUVB
News
- Nuvation Bio (NUVB) Generates $62.9M Annual Revenue Following Successful Erozi Launch [Yahoo! Finance]Yahoo! Finance
- Nuvation Bio Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their LossesGlobeNewswire
- Nuvation Bio Transitions To Commercial Stage With Iptrozi And Safusidenib Progress [Yahoo! Finance]Yahoo! Finance
- Nuvation Bio Stock Up 130% This Past Year as One Fund Discloses $3 Million Buy [Yahoo! Finance]Yahoo! Finance
- Nuvation Bio (NUVB) had its price target lowered by UBS Group AG from $10.00 to $7.00. They now have a "neutral" rating on the stock.MarketBeat
NUVB
Earnings
- 3/2/26 - In-Line
NUVB
Sec Filings
- 3/3/26 - Form 4
- 3/3/26 - Form 4
- 3/3/26 - Form 4
- NUVB's page on the SEC website